New study indicates that tRNA-based drug discovery technology selects anti-HIV bioactive compounds possessing novel antiviral action…

CARY, NC (December 14, 2010) – Trana Discovery, Inc., an infectious disease drug discovery technology company, today announced that a recent study sponsored by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, affirms that bioactive compounds selected ...

Trana Discovery Receives Federal Grants for Anti-HIV and Antibiotic Drug Discovery Assays

Assays based on inhibition of tRNA receive $375,000 in funding…

CARY, NC (November 22, 2010) – Trana Discovery, Inc., an infectious disease drug discovery technology company, today announced that two of the Company’s drug discovery assays, the novel anti-HIV 201 HTS Drug Discovery Assay and the Staphylococcus aureus Antibiotic Drug Discovery ...

Trana Discovery Expands Scientific Advisory Board

World-renowned experts will focus on prioritizing prime disease targets for future assay development and new applications of the unique drug discovery technology…

CARY, NC (March 16, 2010) – Trana Discovery, Inc., an anti-infective drug discovery technology company, today announced three new members of its Scientific Advisory Board. Joining chairperson Michael Ossi, MD are Karin Musier-Forsyth, Ph.D., Ohio Eminent Scholar, The Ohio State University; ...

Trana Discovery Begins Development of Rapid Diagnostic Platform

Rapid diagnostics based on tRNA identification could change how caregivers diagnose serious infectious diseases and prescribe treatments

CARY, NC (February 16, 2010) – Trana Discovery, Inc., an anti-infective drug discovery technology company, today announced that it has begun proof of concept studies on a rapid diagnostic platform that could identify the presence of the vast majority of infection-causing bacteria ...